Zhao Yue, Wang Rui, Shen Xuxia, Pan Yunjian, Cheng Chao, Li Yuan, Shen Lei, Zhang Yang, Li Hang, Zheng Difan, Ye Ting, Zheng Shanbo, Sun Yihua, Chen Haiquan
Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Ann Surg Oncol. 2016 Jun;23(6):2099-105. doi: 10.1245/s10434-015-5043-9. Epub 2016 Feb 2.
Lung adenocarcinoma with micropapillary and solid predominant subtypes was reported to be associated with poor prognosis; however, whether minor components (non-predominant) of micropapillary and solid subtypes predict poor prognosis remains unknown. In this study, we investigated the predictive and prognostic value of lymph node metastasis of minor micropapillary and solid components.
Specimens of resected tumors of 1244 patients were reclassified to determine the predominant subtype and minor components (>5 %, but not predominant). Of these specimens, 105 contained a micropapillary component and 210 contained a solid component. The correlation between each subtype and lymph node metastasis was analyzed, and survival analyses were used to determine the association between each subtype and patient survival.
Adenocarcinomas harboring micropapillary and/or solid components held higher rates of metastatic lymph node stations (25.2 % vs. 15.6 %, p = 0.002; and 24.0 % vs. 14.9 %, p < 0.001, respectively) and lymph nodes (17.3 % vs. 10.1 %, p = 0.004; and 15.5 % vs. 9.7 %, p = 0.001, respectively). Patients with micropapillary and solid components in their tumors showed a shorter median recurrence-free survival (15.8 vs. 62.8 months, p < 0.001; and 20.8 months vs. not reached, p < 0.001) and overall survival (47.0 months vs. not reached, p < 0.001; and 69.0 months vs. not reached, p < 0.001).
Minor components of micropapillary and/or solid subtypes of lung adenocarcinoma are correlated with lymph node metastasis and poor prognosis. Thus, it is beneficial to focus not only on predominant subtypes but also minor components to predict prognoses and make therapeutic strategies more comprehensively.
据报道,具有微乳头和实性为主亚型的肺腺癌与预后不良相关;然而,微乳头和实性亚型的次要成分(非主要成分)是否预示预后不良仍不清楚。在本研究中,我们调查了微乳头和实性次要成分的淋巴结转移的预测和预后价值。
对1244例患者的切除肿瘤标本进行重新分类,以确定主要亚型和次要成分(>5%,但非主要成分)。在这些标本中,105例含有微乳头成分,210例含有实性成分。分析各亚型与淋巴结转移之间的相关性,并采用生存分析来确定各亚型与患者生存之间的关联。
含有微乳头和/或实性成分的腺癌具有更高的转移淋巴结站率(分别为25.2%对15.6%,p = 0.002;以及24.0%对14.9%,p < 0.001)和淋巴结转移率(分别为17.3%对10.1%,p = 0.004;以及15.5%对9.7%,p = 0.001)。肿瘤中含有微乳头和实性成分的患者的无复发生存期中位数较短(分别为15.8个月对62.8个月,p < 0.001;以及20.8个月对未达到,p < 0.001)和总生存期中位数较短(分别为47.0个月对未达到,p < ); 0.001;以及69.0个月对未达到,p < 0.001)。
肺腺癌微乳头和/或实性亚型的次要成分与淋巴结转移和预后不良相关。因此,不仅关注主要亚型,而且关注次要成分,对于更全面地预测预后和制定治疗策略是有益的。